Albumin-encapsulated Nanoparticles of Naproxen Platinum(IV) Complexes with Inflammation Inhibitory Competence Displaying Effective Antitumor Activities in vitro and in vivo

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. doi:10.3322/caac.21551
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.21338
   PubMed Web of Science ®Google Scholar
• Peng Y, Chen L, Ye S, et al. Research and development of drug delivery systems based on drug transporter and nano-formulation. Asian J Pharm Sci. 2020;15(2):220–236. doi:10.1016/j.ajps.2020.02.004
   PubMedGoogle Scholar
• Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2011;63(3):136–151. doi:10.1016/j.addr.2010.04.009
   PubMed Web of Science ®Google Scholar
• Zhao YP, Zhao YN, Ma QS, et al. Carrier-free, dual-functional nanorods via self-assembly of pure drug molecules for synergistic chemo-photodynamic therapy. Int J Nanomed. 2019;14:8665–8683. doi:10.2147/IJN.S224704
   PubMed Web of Science ®Google Scholar
• Johnstone TC, Suntharalingam K, Lippard SJ. The next generation of platinum drugs: targeted Pt(II) agents, nanoparticle delivery, and Pt(IV) prodrugs. Chem Rev. 2016;116(5):3436–3486. doi:10.1021/acs.chemrev.5b00597
   PubMed Web of Science ®Google Scholar
• Li Y, Sun Z, Cui Y, et al. Oxaliplatin derived monofunctional triazole-containing platinum(II) complex counteracts oxaliplatin-induced drug resistance in colorectal cancer. Bioorg Chem. 2021;107:104636. doi:10.1016/j.bioorg.2021.104636
   PubMedGoogle Scholar
• Wang XY, Wang XH, Guo ZJ. Functionalization of platinum complexes for biomedical applications. Acc Chem Res. 2015;48(9):2622–2631. doi:10.1021/acs.accounts.5b00203
   PubMedGoogle Scholar
• Callari M, Aldrich-Wright JR, de Souza PL, Stenzel MH. Polymers with platinum drugs and other macromolecular metal complexes for cancer treatment. Prog Polym Sci. 2014;39(9):1614–1643. doi:10.1016/j.progpolymsci.2014.05.002
   Web of Science ®Google Scholar
• Newman M, Colbern GT, Working PK, Engbers C, Amantea MA. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother Pharmacol. 1999;43(1):1–7. doi:10.1007/s002800050855
   PubMed Web of Science ®Google Scholar
• Ma J, Wang Q, Huang Z, et al. Glycosylated platinum(IV) complexes as substrates for glucose transporters (GLUTs) and organic cation transporters (OCTs) exhibited cancer targeting and human serum albumin binding properties for drug delivery. J Med Chem. 2017;60(13):5736–5748. doi:10.1021/acs.jmedchem.7b00433
   PubMedGoogle Scholar
• Tan XX, Li GS, Wang QP, Wang BQ, Li DC, Wang PG. Small molecular platinum(IV) compounds as antitumor agents. Prog Chem. 2018;30(6):831–846. doi:10.7536/PC171212
   Google Scholar
• Karimi M, Bahrami S, Ravari SB, et al. Albumin nanostructures as advanced drug delivery systems. Expert Opin Drug Deliv. 2016;13(11):1609–1623. doi:10.1080/17425247.2016.1193149
   PubMed Web of Science ®Google Scholar
• Parodi A, Miao J, Soond SM, Rudzińska M, Zamyatnin AA Jr. Albumin nanovectors in cancer therapy and imaging. Biomolecules. 2019;9(6):218. doi:10.3390/biom9060218
   PubMed Web of Science ®Google Scholar
• Hassanin I, Elzoghby A. Albumin-based nanoparticles: a promising strategy to overcome cancer drug resistance. Cancer Drug Resist. 2020;3:930–946. doi:10.20517/cdr.2020.68
   PubMedGoogle Scholar
• Adams JD, Flora KP, Goldspiel BR, Wilson JW, Arbuck SG, Finley R. Taxol: a history of pharmaceutical development and current pharmaceutical concerns. J Natl Cancer Inst. 1993;15:141–147.
   Google Scholar
• Nosrati H, Sefidi N, Sharafi A, Danafar H, Manjili HK. Bovine serum albumin (BSA) coated iron oxide magnetic nanoparticles as biocompatible carriers for curcumin-anticancer drug. Bioorg Chem. 2018;76:501–509. doi:10.1016/j.bioorg.2017.12.033
   PubMed Web of Science ®Google Scholar
• Nosrati H, Danafar H, Rezaeejam H, Gholipour N, Rahimi-Nasrabadi M. Evaluation radioprotective effect of curcumin conjugated albumin nanoparticles. Bioorg Chem. 2020;100:103891. doi:10.1016/j.bioorg.2020.103891
   PubMedGoogle Scholar
• Ding C, Xu Y, Zhao Y, Zhong H, Luo X. Fabrication of BSA@AuNC-based nanostructures for cell fluoresce imaging and target drug delivery. ACS Appl Mater Interfaces. 2018;10(10):8947–8954. doi:10.1021/acsami.7b18493
   PubMed Web of Science ®Google Scholar
• Zhao Y, Cai C, Liu M, et al. An organic solvent-free technology for the fabrication of albumin-based paclitaxel nanoparticles for effective cancer therapy. Colloid Surface B. 2019;183:110394. doi:10.1016/j.colsurfb.2019.110394
   PubMedGoogle Scholar
• Zheng YR, Suntharalingam K, Johnstone TC, et al. Pt(IV) prodrugs designed to bind non-covalently to human serum albumin for drug delivery. J Am Chem Soc. 2014;136(24):8790–8798. doi:10.1021/ja5038269
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Nisticò P, Ciliberto G. Biological mechanisms linked to inflammation in cancer: discovery of tumor microenvironment-related biomarkers and their clinical application in solid tumors. Int J Biol Marker. 2020;35(1_suppl):8–11. doi:10.1177/1724600820906155
   PubMedGoogle Scholar
• Leon-Cabrera S, Schwertfeger KL, Terrazas LI. Inflammation as a target in cancer therapy. Mediators Inflamm. 2019;2019:1971698. doi:10.1155/2019/1971698
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhang Y, Wang Q, et al. Interleukin‐35 in immune-related diseases: protection or destruction. Immunology. 2019;157(1):13–20. doi:10.1111/imm.13044
   PubMedGoogle Scholar
• Cheng Q, Shi H, Wang H, Min Y, Wang J, Liu Y. The ligation of aspirin to cisplatin demonstrates significant synergistic effects on tumor cells. Chem Commun. 2014;50(56):7427–7430. doi:10.1039/c4cc00419a
   PubMed Web of Science ®Google Scholar
• Pathak R, Marrache S, Choi JH, Berding TB, Dhar S. The prodrug platin-A: simultaneous release of cisplatin and aspirin. Angew Chem Int Ed Engl. 2014;53(7):1963–1967. doi:10.1002/anie.201308899
   PubMedGoogle Scholar
• Neumann W, Crews BC, Sárosi MB, et al. Conjugation of cisplatin analogues and cyclooxygenase inhibitors to overcome cisplatin resistance. ChemMedChem. 2015;10(1):183–192. doi:10.1002/cmdc.201402353
   PubMedGoogle Scholar
• Ravera M, Zanellato I, Gabano E, et al. Antiproliferative activity of Pt(IV) conjugates containing the non-steroidal anti-inflammatory drugs (NSAIDs) ketoprofen and naproxen. Int J Mol Sci. 2019;20(12):3074. doi:10.3390/ijms20123074
   PubMedGoogle Scholar
• Li G, Zhang J, Liu Z, et al. Development of a series of 4-hydroxycoumarin platinum(IV) hybrids as antitumor agents: synthesis, biological evaluation and action mechanism investigation. J Inorg Biochem. 2019;194:34–43. doi:10.1016/j.jinorgbio.2019.02.011
   PubMedGoogle Scholar
• Wang Q, Chen Y, Li G, et al. Synthesis and evaluation of bi-functional 7-hydroxycoumarin platinum(IV) complexes as antitumor agents. Bioorg Med Chem. 2019;27(10):2112–2121. doi:10.1016/j.bmc.2019.04.009
   PubMedGoogle Scholar
• Tan J, Li C, Wang Q, et al. A carrier-free nanostructure based on platinum(IV) prodrug enhances cellular uptake and cytotoxicity. Mol Pharmaceutics. 2018;15(4):1724–1728. doi:10.1021/acs.molpharmaceut.8b00070
   PubMedGoogle Scholar
• Spector D, Krasnovskaya O, Pavlov K, et al. Pt(IV) prodrugs with NSAIDs as axial ligands. Int J Mol Sci. 2021;22(8):3817. doi:10.3390/ijms22083817
   PubMedGoogle Scholar
• Zanellato I, Bonarrigo I, Ravera M, Gabano E, Gust R, Osella D. The hexacarbonyldicobalt derivative of aspirin acts as a CO-releasing NSAID on malignant mesothelioma cells. Metallomics. 2013;5(12):1604–1613. doi:10.1039/c3mt00117b
   PubMedGoogle Scholar
• Curci A, Denora N, Iacobazzi RM, et al. Synthesis, characterization, and in vitro cytotoxicity of a Kiteplatin-Ibuprofen Pt(IV) prodrug. Inorg Chim Acta. 2018;472:221–228. doi:10.1016/j.ica.2017.07.019
   Web of Science ®Google Scholar
• Petruzzella E, Sirota R, Solazzo I, Gandin V, Gibson D. Triple action Pt(iv) derivatives of cisplatin: a new class of potent anticancer agents that overcome resistance. Chem Sci. 2018;9(18):4299–4307. doi:10.1039/c8sc00428e
   PubMedGoogle Scholar
• Tolan DA, Abdel‐Monem YK, El‐Nagar MA. Anti‐tumor platinum (IV) complexes bearing the anti‐inflammatory drug naproxen in the axial position. Appl Organometal Chem. 2019;33(3):e4763. doi:10.1002/aoc.4763
   Google Scholar
• Intini FP, Zajac J, Novohradsky V, et al. Novel antitumor platinum(II) conjugates containing the nonsteroidal anti-inflammatory agent diclofenac: synthesis and dual mechanisms of antiproliferative effects. Inorg Chem. 2017;56(3):1483–1497. doi:10.1021/acs.inorgchem.6b02553
   PubMed Web of Science ®Google Scholar
• Chen Y, Wang Q, Li Z, et al. Naproxen platinum(iv) hybrids inhibiting cycloxygenases and matrix metalloproteinases and causing DNA damage: synthesis and biological evaluation as antitumor agents in vitro and in vivo. Dalton Trans. 2020;49(16):5192–5204. doi:10.1039/D0DT00424C
   PubMedGoogle Scholar
• Jin S, Muhammad N, Sun Y, et al. Multispecific platinum(IV) complex deters breast cancer via interposing inflammation and immunosuppression as an inhibitor of COX-2 and PD-L1. Angew Chem Int Ed Engl. 2020;59(51):23313–23321. doi:10.1002/anie.202011273
   PubMedGoogle Scholar
• Wang Q, Huang Z, Ma J, et al. Design, synthesis and biological evaluation of a novel series of glycosylated platinum(iv) complexes as antitumor agents. Dalton Trans. 2016;45(25):10366–10374. doi:10.1039/C6DT01562J
   PubMedGoogle Scholar
• Wang QP, Tan XX, Liu ZF, et al. Design and synthesis of a new series of low toxic naphthalimide platinum(IV) antitumor complexes with dual DNA damage mechanism. Eur J Pharm Sci. 2018;124:127–136. doi:10.1016/j.ejps.2018.08.032
   PubMedGoogle Scholar
• Liu Z, Li Z, Du T, et al. Design, synthesis and biological evaluation of dihydro-2-quinolone platinum(IV) hybrids as antitumor agents displaying mitochondria injury and DNA damage mechanism. Dalton Trans. 2021;50:362–375. doi:10.1039/D0DT03194A
   PubMedGoogle Scholar
• Wang QP, Li GS, Liu ZF, et al. Naphthalimide platinum(IV) compounds as antitumor agents with dual DNA damage mechanism to overcome cisplatin resistance. Eur J Inorg Chem. 2018;40(40):4442–4451. doi:10.1002/ejic.201800799
   Google Scholar
• Wang Q, Chen Y, Li G, et al. A potent aminonaphthalimide platinum(IV) complex with effective antitumor activities in vitro and in vivo displaying dual DNA damage effects on tumor cells. Bioorg Med Chem Lett. 2019;29(20):126670. doi:10.1016/j.bmcl.2019.126670
   PubMedGoogle Scholar
• Sameer AS. Colorectal cancer: molecular mutations and polymorphisms. Front Oncol. 2013;3:114. doi:10.3389/fonc.2013.00114
   PubMedGoogle Scholar
• Wu Y, Hu X, Song L, Zhu J, Yu R. The inhibitory effect of a novel polypeptide fraction from arca subcrenata on cancer-related inflammation in human cervical cancer HeLa cells. Sci World J. 2014;2014:768938. doi:10.1155/2014/768938
   Google Scholar
• Xiao K, Li Y, Luo J, et al. The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. Biomaterials. 2011;32(13):3435–3446. doi:10.1016/j.biomaterials.2011.01.021
   PubMed Web of Science ®Google Scholar
• Sun J, Jiang L, Lin Y, et al. Enhanced anticancer efficacy of paclitaxel through multistage tumor-targeting liposomes modified with RGD and KLA peptides. Int J Nanomed. 2017;12:1517–1537. doi:10.2147/IJN.S122859
   PubMed Web of Science ®Google Scholar
• de Oliveira GA, Cheng RYS, Ridnour LA, et al. Inducible nitric oxide synthase in the carcinogenesis of gastrointestinal cancers. Antioxid Redox Signal. 2017;26(18):1059–1077. doi:10.1089/ars.2016.6850
   PubMed Web of Science ®Google Scholar
• Hu Y, Xiang J, Su L, Tang X. The regulation of nitric oxide in tumor progression and therapy. J Int Med Res. 2020;48(2):300060520905985. doi:10.1177/0300060520905985
   PubMed Web of Science ®Google Scholar
• Özenver N, Efferth T. Small molecule inhibitors and stimulators of inducible nitric oxide synthase in cancer cells from natural origin (phytochemicals, marine compounds, antibiotics). Biochem Pharmacol. 2020;176:113792. doi:10.1016/j.bcp.2020.113792
   PubMed Web of Science ®Google Scholar
• Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 1993;329:2002–2012. doi:10.1056/NEJM199312303292706
   PubMed Web of Science ®Google Scholar
• Vahora H, Khan MA, Alalami U, Hussain A. The potential role of nitric oxide in halting cancer progression through chemoprevention. J Cancer Prev. 2016;21(1):1–12. doi:10.15430/JCP.2016.21.1.1
   PubMedGoogle Scholar
• Vannini F, Kashfi K, Nath N. The dual role of iNOS in cancer. Redox Biol. 2015;6:334–343. doi:10.1016/j.redox.2015.08.009
   PubMed Web of Science ®Google Scholar
• Zhang N, Liu C, Jin L, et al. Ketogenic diet elicits antitumor properties through inducing oxidative stress, inhibiting MMP-9 expression, and rebalancing M1/M2 tumor-associated macrophage phenotype in a mouse model of colon cancer. J Agric Food Chem. 2020;68:11182–11196. doi:10.1021/acs.jafc.0c04041
   PubMed Web of Science ®Google Scholar
• Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol. 2009;27(31):5287–5297. doi:10.1200/JCO.2009.23.5556
   PubMed Web of Science ®Google Scholar
• Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 2011;278(1):16–27. doi:10.1111/j.1742-4658.2010.07919.x
   PubMed Web of Science ®Google Scholar
• Yempala T, Babu T, Karmakar S, et al. Expanding the arsenal of PtIV anticancer agents: multi-action PtIV anticancer agents with bioactive ligands possessing a hydroxy functional group. Angew Chem Int Ed Engl. 2019;58(50):18218–18223. doi:10.1002/anie.201910014
   PubMedGoogle Scholar
• Li Z, Chen Y, Liu Z, et al. Synthesis and biological evaluation of new mono naphthalimide platinum(IV) derivatives as antitumor agents with dual DNA damage mechanism. Monatsh Chem. 2020;151(3):353–367. doi:10.1007/s00706-020-02561-1
   Google Scholar